Skip to main content
TipRanks
Go Ultimate75% OFF

Clinuvel Pharmaceuticals (CUV) Ratios

118 Followers

Clinuvel Pharmaceuticals Ratios

AU:CUV's free cash flow for Q4 2026 was AU$22.93M. For the 2026 fiscal year, AU:CUV's free cash flow was decreased by AU$-1.45M and operating cash flow was AU$24.38M. See a summary of the company’s cash flow.

Financial ratios
RatiosJun 26Jun 25Jun 24Jun 23Jun 22
Liquidity Ratios
Current Ratio14.819.668.817.4410.24
Quick Ratio14.459.348.397.0610.10
Cash Ratio1.068.247.290.942.00
Solvency Ratio1.501.211.311.051.12
Operating Cash Flow Ratio1.921.511.471.452.90
Short-Term Operating Cash Flow Coverage94.980.000.000.000.00
Net Current Asset ValueAU$ 261.36MAU$ 232.03MAU$ 193.95MAU$ 159.72MAU$ 121.33M
Leverage Ratios
Debt-to-Assets Ratio0.010.000.000.010.01
Debt-to-Equity Ratio0.010.000.000.010.01
Debt-to-Capital Ratio0.010.000.000.010.01
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.091.131.141.181.15
Debt Service Coverage Ratio59.119.379.269.839.51
Interest Coverage Ratio498.6710.2510.7812.8114.55
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share0.040.100.100.080.07
Net Debt to EBITDA-0.45-3.91-3.25-0.49-0.75
Profitability Margins
Gross Profit Margin83.18%83.29%91.23%64.59%70.93%
EBIT Margin43.11%58.95%62.52%62.27%55.68%
EBITDA Margin44.16%60.20%63.82%59.20%53.37%
Operating Profit Margin43.11%48.13%54.44%52.23%50.34%
Pretax Profit Margin50.69%54.26%57.47%58.19%52.22%
Net Profit Margin36.07%38.07%40.41%39.08%31.77%
Continuous Operations Profit Margin36.07%38.07%40.41%39.08%31.77%
Net Income Per EBT71.16%70.17%70.32%67.15%60.83%
EBT Per EBIT117.59%112.73%105.57%111.41%103.74%
Return on Assets (ROA)11.45%13.31%15.42%15.73%14.42%
Return on Equity (ROE)12.43%15.02%17.55%18.59%16.63%
Return on Capital Employed (ROCE)14.64%18.70%23.31%24.20%25.24%
Return on Invested Capital (ROIC)10.40%13.10%16.36%16.22%15.32%
Return on Tangible Assets11.46%13.32%15.43%15.76%14.45%
Earnings Yield6.61%6.96%4.57%3.46%2.85%
Efficiency Ratios
Receivables Turnover4.013.463.363.534.06
Payables Turnover12.366.233.309.9373.71
Inventory Turnover2.301.800.732.9110.43
Fixed Asset Turnover10.1713.3311.4227.4724.34
Asset Turnover0.320.350.380.400.45
Working Capital Turnover Ratio0.380.440.490.540.59
Cash Conversion Cycle220.35249.62499.48192.08120.03
Days of Sales Outstanding91.05105.49108.61103.5389.98
Days of Inventory Outstanding158.83202.75501.57125.2935.00
Days of Payables Outstanding29.5358.62110.7036.744.95
Operating Cycle249.88308.24610.18228.82124.98
Cash Flow Ratios
Operating Cash Flow Per Share0.740.820.730.750.81
Free Cash Flow Per Share0.710.810.620.730.80
Dividend Paid and CapEx Coverage Ratio8.9914.664.6112.2923.88
Capital Expenditure Coverage Ratio23.04137.646.6435.9291.78
Operating Cash Flow Coverage Ratio19.0477.7542.1236.9231.73
Operating Cash Flow to Sales Ratio0.390.430.420.470.61
Free Cash Flow Yield6.89%7.85%4.04%4.06%5.37%
Valuation Ratios
Price-to-Earnings (P/E) Ratio15.1214.4221.8828.8735.14
Price-to-Sales (P/S) Ratio5.455.478.8411.2811.16
Price-to-Book (P/B) Ratio1.882.163.845.375.84
Price-to-Free Cash Flow (P/FCF) Ratio14.5212.7424.7724.6218.61
Price-to-Operating Cash Flow Ratio13.8912.6521.0423.9318.40
Price-to-Earnings Growth (PEG) Ratio-2.725.051.360.61-2.20
Enterprise Value Multiple11.905.1810.6018.5620.17
Enterprise Value494.25M296.21M596.62M860.59M707.59M
EV to EBITDA11.905.1810.6018.5620.17
EV to Sales5.263.126.7710.9910.77
EV to Free Cash Flow14.007.2618.9523.9817.94
EV to Operating Cash Flow13.397.2116.1023.3117.75
Tangible Book Value Per Share5.474.813.973.322.53
Shareholders’ Equity Per Share5.474.813.983.332.54
Tax and Other Ratios
Effective Tax Rate0.290.300.300.330.39
Revenue Per Share1.891.901.731.591.33
Net Income Per Share0.680.720.700.620.42
Tax Burden0.710.700.700.670.61
Interest Burden1.180.920.920.930.94
Research & Development to Revenue0.190.080.030.020.02
SG&A to Revenue0.210.280.020.020.02
Stock-Based Compensation to Revenue0.000.020.070.110.09
Income Quality1.091.141.041.211.91

Currency in AUD